Trial Profile
Single-center, open-label study with 14C-radiolabeled ACT-129968 to investigate the mass balance, pharmacokinetics, and metabolism following single oral administration to healthy male subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2015
Price :
$35
*
At a glance
- Drugs Setipiprant (Primary)
- Indications Asthma; Seasonal allergic rhinitis
- Focus Pharmacokinetics
- 17 Feb 2015 New trial record